NuPathe Inc.

NuPathe — Investor Presentation (November 2012)

20 slides from NuPathe's investor presentation, Nov 13, 2012

  1. Slide 1: Corporate Presentation November 13, 2012

    Corporate Presentation November 13, 2012 © 2012 NuPathe Inc. All rights reserved.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All remarks and information that are not historical facts are hereby identified as forward-looking statements for this purpose and include, a

  3. Slide 3: NuPathe – Specialty Pharmaceutical Company

    Innovative solutions for diseases of the central nervous system Focused on key objectives Gaining approval for Zecuity™ Securing commercial partners Conducting additional pre-launch commercial activities Financial resources to execute on key objectives NuPathe – Specialty Pharmaceutical Company

  4. Slide 4: Zecuity – The First and Only Migraine Patch

    Game-changing, disruptive technology for migraine Utilizes proprietary active transdermal delivery technology Uniquely positioned to address migraine-related nausea & vomiting (MRNV) – significant unaddressed disease burden Rapid relief of both headache pain and nausea, very low rate of triptan sens

  5. Slide 5: Zecuity – Harnessing the Power of Sumatriptan

    Applied during migraine to arm or thigh Rapidly delivers sumatriptan, the #1 prescribed Triptan Bypasses GI tract – mouth & gut Simple to use, single use, disposable Long life: issued patents until April 2027 Zecuity – Harnessing the Power of Sumatriptan

  6. Slide 6: Zecuity Addresses Limitations of Other Formulations

    Tablets and MRNV Patients often unwilling or unable to take tablets when nauseated >30% of patients delay/avoid orals – too nauseated/fear of vomiting1,2,3 Tolerability limitations of existing non-orals Nasal sprays: taste issues, nausea, and vomiting are common AEs Injections: high incidence and in

  7. Slide 7: Relieves Pain and Eliminates Nausea within One Hour

    Pivotal phase 3 efficacy data demonstrate: 39% more Zecuity patients had pain relief than placebo at 30 minutes* Sustained pain relief from 2 to 24 hours (P = 0.0015) Significant pain relief at 1 hour (P = 0.0135) Significant elimination of nausea at 1 hour (P = 0.0251) 71% nausea free at 1 hour, re

  8. Slide 8: Pivotal Phase Data Adverse Event Profile

    Pivotal Phase 3 Data Adverse Event Profile Application site events were typical of patches Majority were mild in intensity and transient Minimal incidence of adverse events known as triptan sensations Compared with product labeling for oral (>8%) and injection (>42%) Patch Placebo Application site p

  9. Slide 9: Zecuity NDA Resubmitted – CRL Issues and Actions Taken

    Key CRL Issue Action Taken Skin events of concern Implemented device enhancement Prevents patch from activating when misapplied Packaging Usability Uniformity Containment Modified secondary packaging Usability study demonstrated all patients correctly applied patch during a migraine Additional data

  10. Slide 10: Triptans Dominate the Migraine Market

    31 million migraine sufferers1 Triptan share 94% of migraine prescriptions2 97% of migraine sales2 Preferred class of migraine treatment 3 – 4 triptan trials before moving to different classes (e.g. opioids, DHE)3 Key challenge for triptans: circumventing pervasive migraine-related GI issues Injecti

  11. Slide 11: Millions Remain Underserved

    Triptan Sensations Mimic a cardiovascular event >42% of injection patients3 > 8% of oral tab patients3 Millions Remain Underserved * Linked to a variety of factors, including gastroparesis. Gastroparesis Unreliable absorption Inconsistent Efficacy* >40% of treated patients4 Migraine-Related Nausea (

  12. Slide 12: MRN Drives Tremendous Disease Burden

    Frequent nausea patients are less satisfied with their migraine medications (p < 0.0001)1,2 Frequent nausea patients drive direct medical costs for migraine3 2.2 times as many visits to a specialist 5.4 times as many emergency/urgent care visits 8.2 times higher overnight hospital stay costs Presenc

  13. Slide 13: Pricing and Reimbursement Aligned with Product Positioning

    Insurance is >90% commercial private pay Payors see value in a patch for migraine Recognize cost of poorly controlled migraine patients Acknowledge barrier of GI issues Accept patch as a unique solution Payors indicate broad formulary access Majority Tier 3 with a single step edit Select opportuniti

  14. Slide 14: Quantitative Research Confirms the Market Opportunity for Zecuity

    Physicians rate Zecuity superior to oral, nasal, and injectable triptans for MRN patients on key attributes including: Ability to use early in a migraine attack despite GI issues Frequency of triptan sensations and overall tolerability Elimination of nausea at 1 and at 2 hours 77% of MRN patients wi

  15. Slide 15: Illustrative Market Segment Opportunities

    8 million patients experience nausea in >50% of attacks1 1.5 million patients vomit in 100% of attacks2 Branded injection WAC pricing of $95/migraine Treat 24 migraines per year Illustrative Market Segment Opportunities Migraine-Related Nausea (>50% of Attacks) and Vomiting Segment (100% of Attacks)

  16. Slide 16: Commercialization Strategy

    Secure commercial partnerships Zecuity is a versatile asset within a portfolio Migraine co-morbidity rates include: sleep disorders (52%), depression (45%), arthritis (35%), GERD (26%)1 Headache specialists drive ~ 1/3rd of triptan volume2 ~ 10K headache specialists and neurologists Discrete segment

  17. Slide 17: Pipeline

    NP202: 90-day risperidone biodegradable implant to treat schizophrenia and bipolar disorder Designed to address significant patient non-compliance Continuous delivery reduces psychotic breaks and improves patient functionality1 Seeking global development & commercial partner NP201: 60-day ropinirole

  18. Slide 18: Financial

    Financing & cost containment measures expected to provide cash runway into 4Q13 $28 million financing ($26.3 net proceeds) closed in October Restructured $7.5 million of outstanding debt Headcount reduction and reduced operating expenses Financial

  19. Slide 19: NuPathe – Specialty Pharmaceutical Company: Focused on Key Objectives

    Focused on key objectives Gaining FDA approval for Zecuity Game-changing, disruptive technology for migraine Uniquely positioned to address migraine-related nausea & vomiting (MRNV) – significant unaddressed disease burden Near-term commercial opportunity Attractive specialist–driven market Securing

  20. Slide 20: References

    References Slide 6: 1. National Headache Foundation Patient Survey (June 2008). 2.Silberstein, S. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995;35:387-396. 3. NuPathe market research (2008,2011). 4. US Prescribing Information for Imitrex Nasal Spray. 5. US Prescr

NuPathe — Investor Presentation (November 2012) on 6ix